Amicus Therapeutics Stock News

The European Medicines Agency accepts Amicus Therapeutics' (FOLD) MAA for AT-GAA, a potential treatment for Pompe disease.

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) have been assigned an average rating of Buy from the thirteen ratings firms that are covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 12 month price target among []

PHILADELPHIA, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the European Medicines Agency (EMA) validated the Marketing Authorization Applications (MAA) f

PHILADELPHIA, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the European Medicines Agency (EMA) validated the Marketing Authorization Applications (MAA) for AT-GAA, the Companys investigational two-component therapy for the treatment of Pompe disease. Validation of the application confirms the submission is accepted, and the EMAs centralized procedure with Committee for Medicinal Products for Human Use (CHMP)s assessment begins.

Complete study of the global Lysosomal Storage Disease (LSD) market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding

Amicus Therapeutics Inc. (NASDAQ:FOLD) has a beta value of 1.21 and has seen 1.25 million shares traded in the last trading session. The company, currently valued at $3.03B, closed the last trade at $10.80 per share which meant it lost -$0.54 on the day or -4.76% during that session. The FOLD stock price is -135.09% Amicus Therapeutics Inc. (FOLD) Has A Bright Growth Prospects For 2021 Read More »

PHILADELPHIA, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the 4 th Annual Evercore ISI HealthCONx Virtual Conference on Wednesday, December 1, 2021 at 8:50 a.m. E.T.

PHILADELPHIA, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the 4th Annu

Wall Street brokerages forecast that Amicus Therapeutics, Inc. (NASDAQ:FOLD) will report sales of $86.21 million for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Amicus Therapeutics’ earnings. The lowest sales estimate is $84.66 million and the highest is $87.56 million. Amicus Therapeutics reported sales of $70.57 million during the […]

PHILADELPHIA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced two digital posters for presentation at the 14th International Congress of Inborn Errors of Metabo

PHILADELPHIA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced two digital posters for presentation at the 14th International Congress of Inborn Errors of Metabolism (ICIEM) being held virtually and in Sydney, Australia, November 21-23, 2021.

Squarepoint Ops LLC trimmed its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 94.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,299 shares of the biopharmaceutical companys stock after selling 500,312 shares during the quarter. Squarepoint Ops LLCs holdings in Amicus []

Price T Rowe Associates Inc. MD grew its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 23.1% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,567,676 shares of the biopharmaceutical companys stock after purchasing an additional 482,004 shares during the quarter. Price []

Schonfeld Strategic Advisors LLC lessened its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 73.3% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 12,300 shares of the biopharmaceutical companys stock after selling 33,804 shares during the quarter. Schonfeld Strategic Advisors LLCs []

Amicus Therapeutics (NASDAQ:FOLD) was upgraded by investment analysts at Stifel Nicolaus from a hold rating to a buy rating in a research report issued to clients and investors on Monday, The Fly reports. Other equities analysts also recently issued reports about the stock. BTIG Research initiated coverage on shares of Amicus Therapeutics in a report []